WO2005101989A3 - Derives de piperidine utilises comme modulateurs du recepteur de la chimiokine ccr5 - Google Patents

Derives de piperidine utilises comme modulateurs du recepteur de la chimiokine ccr5 Download PDF

Info

Publication number
WO2005101989A3
WO2005101989A3 PCT/SE2005/000574 SE2005000574W WO2005101989A3 WO 2005101989 A3 WO2005101989 A3 WO 2005101989A3 SE 2005000574 W SE2005000574 W SE 2005000574W WO 2005101989 A3 WO2005101989 A3 WO 2005101989A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulators
chemokine receptor
piperidine derivatives
receptor ccr5
ccr5
Prior art date
Application number
PCT/SE2005/000574
Other languages
English (en)
Other versions
WO2005101989A2 (fr
Inventor
Alan Faull
Howard Tucker
Original Assignee
Astrazeneca Ab
Alan Faull
Howard Tucker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35197429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005101989(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0401057A external-priority patent/SE0401057D0/xx
Priority claimed from SE0500057A external-priority patent/SE0500057D0/sv
Application filed by Astrazeneca Ab, Alan Faull, Howard Tucker filed Critical Astrazeneca Ab
Priority to AU2005235169A priority Critical patent/AU2005235169B2/en
Priority to EP05734934A priority patent/EP1742934A2/fr
Priority to JP2007509422A priority patent/JP2007533735A/ja
Priority to US11/587,330 priority patent/US7615555B2/en
Priority to MXPA06012045A priority patent/MXPA06012045A/es
Priority to BRPI0510126-3A priority patent/BRPI0510126A/pt
Priority to CA002562417A priority patent/CA2562417A1/fr
Publication of WO2005101989A2 publication Critical patent/WO2005101989A2/fr
Publication of WO2005101989A3 publication Critical patent/WO2005101989A3/fr
Priority to IL178650A priority patent/IL178650A0/en
Priority to NO20065319A priority patent/NO20065319L/no
Priority to US12/562,651 priority patent/US20100010007A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

L'invention concerne des composés de formule (I), des compositions contenant ces composés, des méthodes de préparation de ces composés et leur utilisation dans un traitement médical (par exemple la modulation de l'activité du récepteur CCR5 chez un animal à sang chaud).
PCT/SE2005/000574 2004-04-23 2005-04-20 Derives de piperidine utilises comme modulateurs du recepteur de la chimiokine ccr5 WO2005101989A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2005235169A AU2005235169B2 (en) 2004-04-23 2005-04-20 Piperidine derivatives as modulators of chemokine receptor CCR5
EP05734934A EP1742934A2 (fr) 2004-04-23 2005-04-20 Derives de piperidine utilises comme modulateurs du recepteur de la chimiokine ccr5
JP2007509422A JP2007533735A (ja) 2004-04-23 2005-04-20 ケモカイン受容体ｃｃｒ５のモジュレーターとしてのピペリジン誘導体
US11/587,330 US7615555B2 (en) 2004-04-23 2005-04-20 Piperidine derivatives as modulators of chemokine receptor CCR5
MXPA06012045A MXPA06012045A (es) 2004-04-23 2005-04-20 Derivados de piperidina como moduladores del receptor ccr5 de quimiocina.
BRPI0510126-3A BRPI0510126A (pt) 2004-04-23 2005-04-20 derivados de piperidina como moduladores do receptor de quimiocina ccr5
CA002562417A CA2562417A1 (fr) 2004-04-23 2005-04-20 Derives de piperidine utilises comme modulateurs du recepteur de la chimiokine ccr5
IL178650A IL178650A0 (en) 2004-04-23 2006-10-16 Piperidine derivatives as modulators of chemokine receptor ccr5
NO20065319A NO20065319L (no) 2004-04-23 2006-11-20 Piperidinderivater som modulatorer for kjemokinreseptor CCR5
US12/562,651 US20100010007A1 (en) 2004-04-23 2009-09-18 Piperidine derivatives as modulators of chemokine receptor ccr5

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0401057A SE0401057D0 (sv) 2004-04-23 2004-04-23 Chemical Compounds
SE0401057-5 2004-04-23
SE0500057A SE0500057D0 (sv) 2005-01-10 2005-01-10 Chemical compounds
SE0500057-5 2005-01-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/562,651 Division US20100010007A1 (en) 2004-04-23 2009-09-18 Piperidine derivatives as modulators of chemokine receptor ccr5

Publications (2)

Publication Number Publication Date
WO2005101989A2 WO2005101989A2 (fr) 2005-11-03
WO2005101989A3 true WO2005101989A3 (fr) 2006-04-27

Family

ID=35197429

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2005/000574 WO2005101989A2 (fr) 2004-04-23 2005-04-20 Derives de piperidine utilises comme modulateurs du recepteur de la chimiokine ccr5

Country Status (16)

Country Link
US (2) US7615555B2 (fr)
EP (1) EP1742934A2 (fr)
JP (1) JP2007533735A (fr)
KR (1) KR20070007345A (fr)
AR (1) AR048834A1 (fr)
AU (1) AU2005235169B2 (fr)
BR (1) BRPI0510126A (fr)
CA (1) CA2562417A1 (fr)
IL (1) IL178650A0 (fr)
MX (1) MXPA06012045A (fr)
NO (1) NO20065319L (fr)
RU (1) RU2368608C2 (fr)
SA (1) SA05260099B1 (fr)
TW (1) TW200610761A (fr)
UY (1) UY28870A1 (fr)
WO (1) WO2005101989A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007007497D1 (de) * 2006-09-18 2010-08-12 Hoffmann La Roche Octahydropyrroloä3,4-cüpyrrolderivate und ihre verwendung als antivirale mittel
TW200831483A (en) * 2006-12-11 2008-08-01 Astrazeneca Ab Chemical compound
TW200831093A (en) * 2006-12-11 2008-08-01 Astrazeneca Ab Chemical compound
JP2010513272A (ja) * 2006-12-14 2010-04-30 メルク エンド カムパニー インコーポレーテッド アシルビピペリジニル化合物、そのような化合物を含む組成物、及び治療方法
WO2008101728A1 (fr) * 2007-02-23 2008-08-28 K.H.S. Pharma Holding Gmbh Procédé de production d'esters d'azoniaspironortropine et de composés nortropane-3-one
US7977358B2 (en) 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
DK2268646T3 (da) 2008-04-11 2013-11-18 Janssen Pharmaceutica Nv Thiazolopyridin-2-yloxy-phenyl og thiazolopyrazin-2-yloxy-phenyl-aminer som modulatorer af leukotrien-a4-hydrolase
US8217060B2 (en) 2009-05-15 2012-07-10 Janssen Pharmaceutica, Nv Benzimidazole derivatives useful as TRP M8 receptor modulators
EP2456309B1 (fr) 2009-07-24 2015-12-23 GlaxoSmithKline LLC Dérivés de l'azabicyclo[3.2.1]octyle pour leur utilisation dans le traitement du VIH
CN102241664B (zh) * 2010-05-13 2014-11-12 上海医药工业研究院 芳烷二胺类衍生物及其作为抗抑郁症药物的应用
MX2012013465A (es) 2010-05-17 2013-12-02 Array Biopharma Inc Lactamas sustituidas con piperidinilo como moduladores de gpr119.
US20140309226A1 (en) * 2011-11-16 2014-10-16 Array Biopharma Inc. Piperidinyl-substituted cyclic ureas as gpr119 modulators
JP6303250B2 (ja) 2012-12-21 2018-04-04 石原産業株式会社 有害生物防除剤
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US10556899B2 (en) * 2018-02-09 2020-02-11 Sci Pharmtech, Inc. Method for preparing Maraviroc

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999025686A1 (fr) * 1997-11-18 1999-05-27 Teijin Limited Derives d'amine cyclique et leur utilisation en tant que medicaments
EP1013276A1 (fr) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalcanes comme modulateurs de CCR5
WO2001014333A1 (fr) * 1999-08-24 2001-03-01 Astrazeneca Uk Limited Composes de piperidine substitues utiles comme modulateurs de l'activite de recepteurs de chimiokine
WO2001087839A1 (fr) * 2000-05-17 2001-11-22 Astrazeneca Ab Derives de piperidine pharmaceutiquement actifs, en particulier sous forme de modulateurs de l'activite des recepteurs de chimiokine
WO2001090106A2 (fr) * 2000-05-26 2001-11-29 Pfizer Limited Derives du tropane utiles en therapie
WO2003042205A1 (fr) * 2001-11-15 2003-05-22 Astrazeneca Ab Derives de la piperidine et leur utilisation comme modulateurs de l'activite du recepteur de chimiokine (notamment de ccr5)
WO2004054974A2 (fr) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Antagonistes de ccr5 utiles comme agents therapeutiques
WO2004056808A1 (fr) * 2002-12-20 2004-07-08 Astrazeneca Ab Nouveaux derives de piperidine en tant que modulateurs du recepteur ccr5 de la chimiokine
WO2004056773A1 (fr) * 2002-12-20 2004-07-08 Astrazeneca Ab Nouveaux derives de piperidine utilises en tant que modulateurs du recepteur ccr5 des chimiokines
WO2004056809A1 (fr) * 2002-12-20 2004-07-08 Astrazeneca Ab Nouveaux derives de piperidine en tant que modulateurs du recepteur ccr5 de la chimiokine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9100513A (es) 1990-08-06 1992-04-01 Smith Kline French Lab Compuestos
JP2002510327A (ja) * 1997-07-25 2002-04-02 メルク エンド カンパニー インコーポレーテッド 環状アミンケモカイン受容体活性調節剤
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
EP1052992A1 (fr) 1998-02-02 2000-11-22 Merck & Co., Inc. Amines cycliques utilisees en tant que modulateurs de l'activite du recepteur de chemokine
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
GB0005642D0 (en) * 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
EP1352672A3 (fr) * 2002-04-08 2004-01-07 Acrostak Corp. Ballonet PTCA et/ou PTA
US6855724B2 (en) * 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
SE0401656D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
TW200831093A (en) 2006-12-11 2008-08-01 Astrazeneca Ab Chemical compound
TW200831483A (en) 2006-12-11 2008-08-01 Astrazeneca Ab Chemical compound

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999025686A1 (fr) * 1997-11-18 1999-05-27 Teijin Limited Derives d'amine cyclique et leur utilisation en tant que medicaments
EP1013276A1 (fr) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalcanes comme modulateurs de CCR5
WO2001014333A1 (fr) * 1999-08-24 2001-03-01 Astrazeneca Uk Limited Composes de piperidine substitues utiles comme modulateurs de l'activite de recepteurs de chimiokine
WO2001087839A1 (fr) * 2000-05-17 2001-11-22 Astrazeneca Ab Derives de piperidine pharmaceutiquement actifs, en particulier sous forme de modulateurs de l'activite des recepteurs de chimiokine
WO2001090106A2 (fr) * 2000-05-26 2001-11-29 Pfizer Limited Derives du tropane utiles en therapie
WO2003042205A1 (fr) * 2001-11-15 2003-05-22 Astrazeneca Ab Derives de la piperidine et leur utilisation comme modulateurs de l'activite du recepteur de chimiokine (notamment de ccr5)
WO2004054974A2 (fr) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Antagonistes de ccr5 utiles comme agents therapeutiques
WO2004056808A1 (fr) * 2002-12-20 2004-07-08 Astrazeneca Ab Nouveaux derives de piperidine en tant que modulateurs du recepteur ccr5 de la chimiokine
WO2004056773A1 (fr) * 2002-12-20 2004-07-08 Astrazeneca Ab Nouveaux derives de piperidine utilises en tant que modulateurs du recepteur ccr5 des chimiokines
WO2004056809A1 (fr) * 2002-12-20 2004-07-08 Astrazeneca Ab Nouveaux derives de piperidine en tant que modulateurs du recepteur ccr5 de la chimiokine

Also Published As

Publication number Publication date
US20070167442A1 (en) 2007-07-19
SA05260099B1 (ar) 2009-12-22
TW200610761A (en) 2006-04-01
WO2005101989A2 (fr) 2005-11-03
US7615555B2 (en) 2009-11-10
MXPA06012045A (es) 2007-01-25
NO20065319L (no) 2007-01-23
AU2005235169B2 (en) 2008-09-18
JP2007533735A (ja) 2007-11-22
IL178650A0 (en) 2007-02-11
RU2006138663A (ru) 2008-05-27
KR20070007345A (ko) 2007-01-15
RU2368608C2 (ru) 2009-09-27
US20100010007A1 (en) 2010-01-14
EP1742934A2 (fr) 2007-01-17
CA2562417A1 (fr) 2005-11-03
AU2005235169A1 (en) 2005-11-03
UY28870A1 (es) 2005-11-30
BRPI0510126A (pt) 2007-06-26
AR048834A1 (es) 2006-05-31

Similar Documents

Publication Publication Date Title
WO2005101989A3 (fr) Derives de piperidine utilises comme modulateurs du recepteur de la chimiokine ccr5
WO2001087839A8 (fr) Derives de piperidine pharmaceutiquement actifs, en particulier sous forme de modulateurs de l&#39;activite des recepteurs de chimiokine
TW200630326A (en) Chemical compounds
UA88303C2 (ru) Производные пиперидина, которые имеют активность по отношению к ccr5 (хемокинового рецептора 5)
RS20070077A (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflamatory diseases
PT1778680E (pt) Derivados espirocíclicos de ciclo-hexano
WO2003042177A8 (fr) Derives de la piperidine et leurs utilisations comme modulateurs de l&#39;activite du recepteur de la chemokine (specialement du ccr5)
MXPA04004503A (es) Derivados de piperina y su uso como moduladores de actividad receptora de quimiocina (especialmente ccr5).
WO2007114921A3 (fr) Formulations pharmaceutiques : sels de 8-[{1-(3,5-bis (trifluoromethy1)pheny1)-e thoxy}-methy1]-8-pheny1-1,7-diaza-spiro[4.5] decan-2-one et méthodes de traitement utilisant lesdits sels
TW200505856A (en) Chemical compounds
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
UA83832C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и их применение
WO2004056808A8 (fr) Nouveaux derives de piperidine en tant que modulateurs du recepteur ccr5 de la chimiokine
WO2004056809A8 (fr) Nouveaux derives de piperidine en tant que modulateurs du recepteur ccr5 de la chimiokine
MXPA05011788A (es) Compuestos quimicos.
SE0401656D0 (sv) Chemical compounds
SE0302090D0 (sv) Chemical compounds
UA88002C2 (ru) Производной пиперидина как модуляторы рецептора ccr5 хемокина, способ их получения и фармацевтическая композиция на их основе
IL181666A0 (en) Indolin-2-one pyridine derivatives, preparation and therapeutic use thereof
SE0303396D0 (sv) Chemical compounds
TW200510307A (en) Chemical compounds
NO20063617L (no) Diarylmetylidenpiperidinderivater, fremstilling og anvendelse derav
SE0402636D0 (sv) Chemical compounds
NO20053539L (no) Nye piperidinderivater som modulatorer for kjemokinreseptor CCR5.
UA87327C2 (ru) Производные бензимидазола, композиция, которая их содержит, их получение и применение

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005235169

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2562417

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006/08532

Country of ref document: ZA

Ref document number: 200608532

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 178650

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/012045

Country of ref document: MX

Ref document number: 06105172

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 550683

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007167442

Country of ref document: US

Ref document number: 1020067021878

Country of ref document: KR

Ref document number: 11587330

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2007509422

Country of ref document: JP

Ref document number: 12006502101

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005235169

Country of ref document: AU

Date of ref document: 20050420

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005235169

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005734934

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 6345/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006138663

Country of ref document: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200580020985.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020067021878

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005734934

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0510126

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 11587330

Country of ref document: US